Coldstream Capital Management’s Q32 Bio QTTB Stock Holding History

Coldstream Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,114	Closed	-$1.84K	–	3452
2025 Q1	$1.84K	Buy	+1,114	New	+$3K	﹤0.01%	3031

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coldstream Capital Management's QTTB Position: Q2 2025 in Review

Coldstream Capital Management sold out of Q32 Bio (QTTB) in Q2 2025, closing a stake of 1,114 shares — an estimated $1.84K sold.

Coldstream Capital Management first reported a position in QTTB in Q1 2025 and held it in 1 quarter. The position peaked at $1.84K in Q1 2025. 61 funds tracked by Wall St. Rank hold QTTB as of Q2 2025.

Coldstream Capital Management reported no remaining Q32 Bio position as of Q2 2025 after selling out during the quarter.
Coldstream Capital Management sold 1,114 Q32 Bio shares in Q2 2025, an estimated $1.84K.
Coldstream Capital Management first reported a position in Q32 Bio in Q1 2025 and held it in 1 quarter.
Coldstream Capital Management's Q32 Bio position peaked at $1.84K in Q1 2025.
61 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.